Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
|Articles|September 13, 2011
Robotic Surgery in Gynecology
Author(s)Neena Agarwala, MD, MSc, FACOG
Download the .PPT version of this presentation for off line viewing (1.92 MB)Return to Power Point Presentations Indexsubmit your own material for publication via email with your files attached
Advertisement
Advertisement
Related to this article
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Chrisandra Shufelt, MD, on cardiovascular risk assessment and menopause care
4
Chrisandra Shufelt, MD, on cardiovascular prevention at menopause
5